Elie El Rassy1, Marwan Ghosn1, Fadi Farhat1,2, Ziad Bakouny1, Tarek Assi1, Georges Chahine1,3, Fadi Nasr1,4, Fady Ghassan Haddad1, Fadi El Karak1, Joseph Kattan1,5. 1. Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. 2. Department of Medical Oncology, Hammoud Hospital, Saida, Lebanon. 3. Department of Medical Oncology, Notre Dame de Secours Hospital, Byblos, Lebanon. 4. Department of Medical Oncology, Mount Lebanon Hospital, Hadath, Lebanon. 5. Department of Medical Oncology, Saint Joseph Hospital, Baouchrieh, Lebanon.
Abstract
BACKGROUND: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer. METHODS: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012. RESULTS: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common. CONCLUSION: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.
BACKGROUND: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer. METHODS: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012. RESULTS: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common. CONCLUSION: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.
Entities:
Keywords:
Adverse events; Breast cancer; Docetaxel; Safety; Toxicity
Authors: Hamdy Abdel Azim; Yasser Salah El Din Abdal-Kader; Mohamed Mahmoud Mousa; Raafat Abdel Malek; Michael Kheir Abdalmassih; Noha Yehia Ibrahim Journal: Asian Pac J Cancer Prev Date: 2015
Authors: Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel Journal: N Engl J Med Date: 2005-06-02 Impact factor: 91.245